Forget 2019.

We’re coming to ya like it’s 1990 to report that dose-escalated radiation (without a better dosimetric understanding of how it affects the lungs and heart, or without GARD) doesn’t work for esophageal cancer. The French PRODIGE-26 trial reports that a 26 Gy boost versus a standard 10 Gy boost following 40 Gy to elective nodes concurrent with FOLFOX-4 x 6 cycles does nothing to improve cancer or survival outcomes, concluding “50Gy should be definitely admitted as a standard dose.” Whew glad that’s cleared up. | Crehange, ASTRO 2021